Skip to main content
Premium Trial:

Request an Annual Quote

Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker

Premium

Sirnaomics said last week that it has signed a deal with Chinese drug company Guangdong Zhongsheng Pharmaceutical to develop siRNA-based therapeutics for diabetic retinopathy and age-related macular degeneration.

The partnership will specifically include STP601, Sirnaomics' preclinical treatment for ocular neovascularization diseases, in the Greater China and Southeast Asian markets.

Guangdong Zhongsheng has agreed to pay Sirnaomics up to $9.75 million in upfront and milestone payments under the deal, as well as royalties and market-territory sharing considerations.

Additional terms were not disclosed.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.